(PDF) P1.01-110 Three Specific HER2 Mutations Predict

P1.01-110 Three Specific HER2 Mutations Predict Favorable Outcomes in Advanced Lung Cancer Patients Treated With Afatinib

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.667

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

P1.01-56 Concurrent Mutations in Chinese Lung Cancer Patients Carrying HER2 Genomic Aberrations

Journal of Thoracic Oncology

Respiratory Medicine

English

P13 Impact of ErbB Mutations on Clinical Outcomes in Afatinib- Or Erlotinib-Treated Patients With SCC of the Lung

Journal of Thoracic Oncology

Respiratory Medicine

English

HER2 Mutations in Chinese Patients With Non-Small Cell Lung Cancer

English

P088 Distribution of Different HER2 Mutations and Their Impact on Clinical Responses to Afatinib in HER2-Mutant Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-92 a Phase II Study of Afatinib Treatment for Elderly Patients With Previously Untreated Advanced NSCLC Harboring EGFR Mutations

Journal of Thoracic Oncology

Respiratory Medicine

English

Afatinib Treatment in Advanced Non-Small Cell Lung Cancer

Lung Cancer: Targets and Therapy

English

P1.01-26 Single-Centre Experience of Clinical Outcomes for Advanced Lung Cancer Patients in Phase I Clinical Trials

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-103 Leukocyte Telomere Length as a Novel Biomarker in Advanced Lung Adenocarcinoma Patients Treated With Gefitinib

Journal of Thoracic Oncology

Respiratory Medicine

English

BioPATH: A Biomarker Study in Asian Patients With HER2+ Advanced Breast Cancer Treated With Lapatinib and Other Anti-Her2 Therapy

Cancer Research and Treatment

Cancer Research

English